Japan · Delayed Price · Currency is JPY Otsuka Holdings Earnings Call Transcripts
Fiscal Year 2026
-
The acquisition brings a late-stage PTSD treatment, TSND-201, into the portfolio for $700M upfront plus up to $525M in milestones. The deal leverages existing CNS expertise and targets a large unmet need, with U.S. launch aimed for 2030.
Fiscal Year 2025
-
Record revenue and profit highs were achieved in FY 2025, driven by robust pharma and NC business growth. Despite expected profit decline in FY 2026 due to generic competition, strong product launches and strategic investments position the company for sustainable long-term growth.
-
Revenue and profits grew year-over-year in Q2 FY2025, led by strong pharmaceutical and nutraceutical sales. Upward revisions to full-year profit and dividend guidance reflect robust business performance, ongoing pipeline expansion, and enhanced capital efficiency.
Fiscal Year 2024
-
Revenue and business profit saw double-digit year-on-year growth, led by strong Pharmaceutical and Nutraceutical sales. Full-year forecasts were revised upward, and a major acquisition and share repurchase were announced.